The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview
Abstract
INTRODUCTION: Social anxiety disorder (SAD) is associated with scarce functioning and poor quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are currently first-line treatments, side effects are common and affect treatment compliance in approximately 50% of patients. This review aimed to summarize data on the efficacy of unlabeled molecules for SAD treatment. AREAS COVERED: Research in the main psychiatric databases was conducted (PubMed, PsychINFO, and EMBASE-Ovid) to select studies investigating the efficacy of marketed molecules not labeled for SAD treatment. EXPERT OPINION: Pregabalin at high doses (450-600 mg/day) appears to be a reliable alternative strategy for SAD treatment. Among the SSRIs not labeled for SAD, citalopram showed the most promising results. Quetiapine, levetiracetam, and other antidepressants/serotonergic agents, such as fluoxetine, duloxetine, monoamine oxidase inhibitors, tricyclics, mirtazapine, atomoxetine, nefazodone, vilazodone, and buspirone, presented negative, limited, or contrasting results. Data on anticonvulsants, olanzapine, tiagabine, and ketamine were positive, but preliminary. The risk/benefit ratio must be considered in the prescription of unlabeled compounds; treatment with pregabalin may be associated with somnolence and dizziness. Future research may contribute to the identification of targeted molecules for the treatment of this disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence from preclinical studies suggests that activation of α7-nAChR signalling results in suppression or prevention of anxiety. 20–22”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Kotov, R., Krueger, R. F., Watson, D., Achenbach, T. M., Althoff, R. R., Bagby, R. M., Brown, T. A., Carpenter, W. T., Caspi, A., Clark, L. A., et al. (2017) · Journal of Abnormal Psychology · doi:10.1037/abn0000258 · Cited by 3,335
Armijo‐Olivo, S., Stiles, C. R., Hagen, N. A., Biondo, P. D., & Cummings, G. G. (2012) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01516.x · Cited by 1,539 · cited 1×
“According to the results of the present review, if patients are resistant to first-line treatments, clinicians can switch to citalopram, which showed the most promising results in terms of efficacy in patients with SAD among unlabeled antidepressants [64].”
ResultStein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 1×
“In fact, some antidepressants are considered first-line treatments for SAD, especially SSRIs such as escitalopram, fluvoxamine, paroxetine, and sertraline [15,60], and the SNRI venlafaxine [60].”
BackgroundCarpenter, J. K., Andrews, L. A., Witcraft, S. M., Powers, M. B., Smits, J. A. J., & Hofmann, S. G. (2018) · Depression and Anxiety · doi:10.1002/da.22728 · Cited by 846 · cited 4×
“The following were excluded: (1) reviews, meta-analyses, commentaries, case reports, case studies, interim reports, pooled analyses, and study protocols; (2) studies conducted on animals; (3) studies involving drugs that have been approved by both the FDA and EMA for treating SAD (sertraline, paroxetine, escitalopram,…”
BackgroundInfluentialSocial fears and social phobia in the USA: results from the National Comorbidity survey replication
Ruscio, A. M., Brown, T. A., Chiu, W. T., Sareen, J., Stein, M. B., & Kessler, R. C. (2008) · Psychological Medicine · doi:10.1017/s0033291707001699 · Cited by 835 · cited 1×
“Indeed, it is estimated that only one-third of individuals with lifelong SAD receive specific treatment for this disorder [11].”
BackgroundMayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680 · cited 1×
“Another aspect to be considered in the choice of pharmacotherapy is the side-effect profile [16,17].”
BackgroundPhenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 1×
“Phenelzine overcame both atenolol and placebo in 74 patients with SAD randomly assigned to one of the three study arms, with a significantly higher response rate (based on CGI change scores) reported by patients treated with phenelzine [31].”
Method
Research works printed but not linked: 6
- World Health Organization, 2017, Depression and other common mental disorders: global health estimates
- Williams T, 2017, Cochrane Database Syst Rev, 10, CD001206
- Van Ameringen M, 1993, J Clin Psychiatry, 54, 27
- Careri JM, 2015, Prim Care Companion CNS Disord, 17
- Kinrys G, 2003, Int Clin Psychopharmacol, 18, 169
- Tikal K, 1993, Cesk Psychiatr, 89, 163
Cited by
He, Y., Polymeropoulos, C. M., Mohrman, M. A., Truslow, S. O., Xiao, C., Wu, Y., Birznieks, G., & Polymeropoulos, M. H. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.84 · Cited by 5
“23 LSAS total score ≥ 60 was reported to be an optimal cut-off value for generalised SAD, 24 and it is therefore likely that most participants in our study may have had underlying SAD although never previously formally diagnosed.”
InfluentialYang, Y., Lan, Q., Liang, W., Zhou, M., Zhao, W., & Gong, P. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111220 · Cited by 1
Metadata
- Authors
- Caldiroli, A., Capuzzi, E., Tagliabue, I., Ledda, L., Clerici, M., & Buoli, M.
- Affiliations
- Department of Mental Health and Addiction, ASST Monza, Monza, Italy
- University of Milano-Bicocca (IT)
- University of Milan (IT)
- Corresponding author
- Caldiroli, Alice
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2022-12-22
- Volume
- 24
- Issue
- 2
- Pages
- 207-219
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4311763675
- Cited by
- 2
- References
- 70
- Citations by year
- 2025: 1 · 2024: 1
- FWCI
- 0.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- social anxiety disorder, off-label drug use, pregabalin, citalopram, quetiapine, levetiracetam, antidepressants, antiepileptic drugs, ketamine, olanzapine, tiagabine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, treatment side effects, medication adherence
- MeSH terms
- Pregabalin, Phobia, Social, Adult, Antidepressive Agents, Humans, Quality of Life, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. https://app.cochat.ai/papers/10.1080/14656566.2022.2159373
- The paper
- Caldiroli, A., Capuzzi, E., Tagliabue, I., Ledda, L., Clerici, M., & Buoli, M. (2023). New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2022.2159373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.